Iron Chelation Therapy for Myelodysplastic Syndrome: If and When
- 1 February 2006
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 81 (2), 197-198
- https://doi.org/10.4065/81.2.197
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposalsBritish Journal of Haematology, 2005
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision MakingJournal of Clinical Oncology, 2005
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- Adherence to deferoxamine therapy: Heeding Hippocrates and OslerAmerican Journal of Hematology, 2004
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of lifeBritish Journal of Haematology, 2003
- The World Health Organization (WHO) classification of the myeloid neoplasmsBlood, 2002
- Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?The Hematology Journal, 2000
- The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overloadBritish Journal of Haematology, 1996